Last reviewed · How we verify
YH12852 IR 0.1mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
YH12852 IR 0.1mg (YH12852 IR 0.1mg) — Yuhan Corporation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| YH12852 IR 0.1mg TARGET | YH12852 IR 0.1mg | Yuhan Corporation | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- YH12852 IR 0.1mg CI watch — RSS
- YH12852 IR 0.1mg CI watch — Atom
- YH12852 IR 0.1mg CI watch — JSON
- YH12852 IR 0.1mg alone — RSS
Cite this brief
Drug Landscape (2026). YH12852 IR 0.1mg — Competitive Intelligence Brief. https://druglandscape.com/ci/yh12852-ir-0-1mg. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab